Celgene sells its Otezla to Amgen for $13.4 billion

Amgen to acquire Otezla from Celgene for $13.4B in cash Amgen (AMGN) announced that it has entered into an agreement with Celgene (CELG) in connection with its previously announced merger with Bristol-Myers (BMY) to acquire worldwide rights to Otezla, “the only oral, non-biologic treatment for psoriasis and psoriatic arthritis,” and certain related assets and liabilities, …

Bristol-Myers comments on Celgene’s purchase

Bristol-Myers sees ‘meaningful financial benefits’ from Celgene transaction. Bristol-Myers Squibb (BMY) said an updated its investor presentation about the Celgene (CELG) transaction. The company said, “The Celgene transaction is the natural next step in Bristol-Myers Squibb’s proven strategy that has consistently delivered results for over a decade. Through a disciplined approach to driving innovation, focusing …

Celgene announces positive breast cancer data

Celgene announces IMpassion130 study meets co-primary endpoint of PFS Celgene (CELG) announced that the Phase III IMpassion130 study met its co-primary endpoint of progression-free survival, or PFS. This is the first phase III study to demonstrate a statistically significant PFS improvement in first-line metastatic or unresectable locally advanced triple negative breast cancer, or TNBC, a …

FDA rejects Celgene’s application for ozanimod

Celgene receives Refusal to File letter from FDA regarding ozanimod NDA Celgene Corporation (CELG) announced that it has received a Refusal to File letter from the United States Food and Drug Administration regarding its New Drug Application for ozanimod in development for the treatment of patients with relapsing forms of multiple sclerosis. Ozanimod is a …

Celgene is acquiring Impact Biomedicines for $7B

Celgene to acquire Impact Biomedicines, adds Fedratinib to pipeline Celgene (CELG) and privately held Impact Biomedicines announced the signing of a definitive agreement in which Celgene will acquire Impact Biomedicines, which is developing fedratinib for myelofibrosis and polycythemia vera. Under the terms of the agreement, Celgene will pay approximately $1.1B upfront and up to $1.25B in …

Celgene’s Revlimid fails in lymphoma patients

Celgene’s Revlimid in follicular lymphoma shows no superiority vs. standard Celgene (CELG) and the Lymphoma Academic Research Organisation reported results from a phase III, randomized, open-label, international clinical study evaluating Revlimid plus rituximab – R2 – followed by R2 maintenance compared to the standard of care with rituximab plus chemotherapy followed by rituximab maintenance in …

Juno Therapeutics and Celgene higher on lymphoma data

Juno Therapeutics, Celgene report additional data from TRANSCEND study Juno Therapeutics (JUNO) and Celgene Corporation (CELG) released additional data from the TRANSCEND study of JCAR017 in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. TRANSCEND is an open-label, multicenter Phase 1 study to determine the safety, pharmacokinetics, and antitumor activity of JCAR017 in adult …

Celgene tumbles following failure of its Crohn’s disease drug

Celgene says GED-0301 phase III REVOLVE trial to discontinue  Celgene Corporation (CELG) announced that the GED-0301 phase III REVOLVE trial in Crohn’s disease and the extension trial will discontinue. Celgene has decided to stop the trials following an October recommendation of the Data Monitoring Committee, which assessed overall benefit/risk during a recent interim futility analysis. …

Barron’s is bullish on Goldman Sachs, bearish on Snap On

Barron’s, the weekly publication owned by the Wall Street Journal, in its latest issue mentions several names:   BULLISH   MENTIONS: Biotech could be headed for a revival – Big biotechnology stocks could be headed for a revival, Ben Levisohn writes in this week’s edition of Barron’s. Biogen (BIIB) and Celgene (CELG) finished the week higher, AbbVie (ABBV) …

Barron’s is bullish on biotechs, Target

Barron’s, the weekly publication owned by the Wall Street Journal, in its latest issue mentions several names:  BULLISH  MENTIONS Local Chinese consumer plays to have significant advantages – China’s 19th Communist Party Congress gave expanded powers to President Xi Jinping to wield in a second five-year term as the country’s leader, endorsing the continued shift …

Shares of bluebird bio Jump on ASCO Presentation

American Society of Clinical Oncology’s #ASCO Annual Meeting is taking place June 2 to June 6 in Chicago. Several pharmaceutical firms and biotechnology companies are presenting their new drugs and/or present progress on the status of their drugs under development. bluebird bio BLUE is one of the presenters.

bluebird bio, and Celgene presented data on bb2121, their investigational anti-BCMA CAR T cell therapy for multiple myeloma.